Stock Analysis of Candel Therapeutics Inc (CADL) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code CADL
Close 8.90
Change 0.280 / 3.25 %
Volume 628132
Vol Change -395862.00 / 38.66 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Candel Therapeutics Inc
PE (TTM)

-1727.29

Very Poor
Price / Book

2876.93

Very Poor
Price / Sales

36340.30

Very Poor
Piotroski F Score

0.0

Very Poor
Market Cap

264727 K

Enterprise Value

251103 K

ROA (TTM)

-75.05

Very Poor
ROE (TTM)

-166.56

Very Poor
Net Margin (TTM)

-2103.89

Very Poor
Revenue

75.20 %

31000.00
Net Profit

69.88 %

-31927.00 K
Debt to Equity

1.71

Not Good
Altman Z Score

-0.994

Very Poor
Quick Ratio

0

Poor
Cash Ratio

2.50

Good


Highs/Lows of Candel Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week7.8 14.10 % 0.513 % 9.367.430-May-2428-May-24
Two Week11.5 22.61 % 0.486 % 13.10997.421-May-2428-May-24
One Month7.05 26.24 % 4.80 % 14.36.9416-May-2401-May-24
Three Month1.86 378.49 % 3.56 % 14.31.3416-May-2418-Mar-24
Six Months0.899 889.99 % 15.54 % 14.30.7716-May-2405-Dec-23
One year1.51 489.40 % 26.26 % 14.30.6616-May-2403-Nov-23
Two year3.77 136.07 % 27.72 % 14.30.6616-May-2403-Nov-23


Technical View of Candel Therapeutics Inc
RSI

49.47

Neutral
MACD

0.510

Bearish
ADX

42.68

Mild Bullish
Super Trend

13.24

Strong Bearish
Williams %R

-78.26

Mild Bullish
CCI

-71.78

Neutral


EMA 5

9.02

Mild Bearish
EMA 15

9.59

Mild Bearish
EMA 50

7.52

Bullish
EMA 100

5.44

Bullish
SMA 100

4.25

Bullish
SMA 200

2.65

Strong Bullish
SMA 5 / 20

8.53 / 10.24

Strong Bearish
SMA 15 / 50

10.44 / 7.01

Strong Bullish
SMA 50 / 200

7.01 / 2.65

Strong Bullish




Charts of Candel Therapeutics Inc


Returns of Candel Therapeutics Inc with Peers
Period / StockCADLCLLSBDTXENTA
1 Week14.10%-3.90%-2.25%3.66%
1 Mth26.24%5.86%-14.18%-9.24%
3 Mth378.49%5.04%-7.09%-13.22%
6mth889.99%-9.06%104.27%33.51%
1 Year489.40%42.63%156.99%-46.89%
2 Year136.07%-25.14%182.84%-68.77%
5 Years--82.93%--86.22%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Candel Therapeutics Inc with Peers
Ratio / StockCADLCLLSBDTXENTA
PE-1727.29-1.51-778.00-2.00
P/B2876.931.86579.361.22
ROA-75.05-41.94-54.73-30.98
ROE-166.56-124.89-74.47-60.88
Debt To Equity1.710.4970.02670.0243
Revenue31000.00
75.20 % 		16496.00 K
13.95 % 		0
% 		79204.00 K
8.07 %
Net Income-31927.00 K
69.88 % 		-85010.00 K
13.86 % 		-82442.00 K
90327.67 % 		-133816.00 K
9.91 %


Technicals of Candel Therapeutics Inc with Peers
Technical / StockCADLCLLSBDTXENTA-
ADX42.6818.5221.9019.52
CMF-0.1320.449-0.292-0.0087
MFI43.2133.1723.9332.48
RSI49.4741.5639.6944.92
MACD Abv SignalFalseFalseFalseTrue
Price Above 50 MATrueFalseFalseFalse-
Price Above 200 MATrueTrueTrueTrue-


About : Candel Therapeutics Inc

Address : 117 Kendrick Street, Needham, MA, United States, 02494
Tel : 617 916 5445
URL : https://www.candeltx.com
Code : CADL, ISIN : US1374041093, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 27_Jul_2021
Employee Count : 42

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)